Progressive breathlessness in COPD

the role of hyperinflation and its pharmacological management

David Brendan Price, Daryl Freeman, Alan Kaplan, Anders Østrem, James Reid, Thys van der Molen

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Breathlessness, along with the associated inability to engage in normal activity, is one of the most distressing symptoms for patients with chronic obstructive pulmonary disease (COPD). If treatment for breathlessness is started early in the disease, physical activity could, in theory, be improved or maintained; this may slow the progression of symptoms towards disability and improve quality of life. A significant cause of breathlessness in COPD is hyperinflation of the lungs due to air trapping, which occurs largely as a result of airflow limitation. Regular exercise reduces the respiratory demand of muscles and, by inference, the impact of air trapping during less intensive activities. Moreover, although airflow limitation in COPD is poorly responsive to anti-inflammatory drugs and less responsive to bronchodilators than in asthma, bronchodilators are clinically proven to bring perceivable symptom improvements in COPD. These improvements correlate with improvements in air trapping indices, which can be significant even in the absence of significant change in forced expiratory volume in 1 second (FEV(1)). The rationale for treatment in COPD, therefore, differs to that for asthma. Understanding of the pathophysiology of COPD improves our chances of achieving an effective intervention with the hope of a better quality of life for patients.
Original languageEnglish
Pages (from-to)285-293
Number of pages9
JournalPrimary Care Respiratory Journal
Volume14
Issue number6
Early online date4 Nov 2005
DOIs
Publication statusPublished - Dec 2005

Fingerprint

Dyspnea
Chronic Obstructive Pulmonary Disease
Pharmacology
Bronchodilator Agents
Air
Asthma
Quality of Life
Exercise
Respiratory Muscles
Forced Expiratory Volume
Anti-Inflammatory Agents
Lung
Therapeutics
Pharmaceutical Preparations

Cite this

Progressive breathlessness in COPD : the role of hyperinflation and its pharmacological management. / Price, David Brendan; Freeman, Daryl; Kaplan, Alan; Østrem, Anders; Reid, James; van der Molen, Thys.

In: Primary Care Respiratory Journal, Vol. 14, No. 6, 12.2005, p. 285-293.

Research output: Contribution to journalArticle

Price, David Brendan ; Freeman, Daryl ; Kaplan, Alan ; Østrem, Anders ; Reid, James ; van der Molen, Thys. / Progressive breathlessness in COPD : the role of hyperinflation and its pharmacological management. In: Primary Care Respiratory Journal. 2005 ; Vol. 14, No. 6. pp. 285-293.
@article{c03b9ee3208a47b1980ee59075f53079,
title = "Progressive breathlessness in COPD: the role of hyperinflation and its pharmacological management",
abstract = "Breathlessness, along with the associated inability to engage in normal activity, is one of the most distressing symptoms for patients with chronic obstructive pulmonary disease (COPD). If treatment for breathlessness is started early in the disease, physical activity could, in theory, be improved or maintained; this may slow the progression of symptoms towards disability and improve quality of life. A significant cause of breathlessness in COPD is hyperinflation of the lungs due to air trapping, which occurs largely as a result of airflow limitation. Regular exercise reduces the respiratory demand of muscles and, by inference, the impact of air trapping during less intensive activities. Moreover, although airflow limitation in COPD is poorly responsive to anti-inflammatory drugs and less responsive to bronchodilators than in asthma, bronchodilators are clinically proven to bring perceivable symptom improvements in COPD. These improvements correlate with improvements in air trapping indices, which can be significant even in the absence of significant change in forced expiratory volume in 1 second (FEV(1)). The rationale for treatment in COPD, therefore, differs to that for asthma. Understanding of the pathophysiology of COPD improves our chances of achieving an effective intervention with the hope of a better quality of life for patients.",
author = "Price, {David Brendan} and Daryl Freeman and Alan Kaplan and Anders {\O}strem and James Reid and {van der Molen}, Thys",
year = "2005",
month = "12",
doi = "10.1016/j.pcrj.2005.08.005",
language = "English",
volume = "14",
pages = "285--293",
journal = "Primary Care Respiratory Journal",
issn = "1471-4418",
publisher = "Primary Care Respiratory Society UK",
number = "6",

}

TY - JOUR

T1 - Progressive breathlessness in COPD

T2 - the role of hyperinflation and its pharmacological management

AU - Price, David Brendan

AU - Freeman, Daryl

AU - Kaplan, Alan

AU - Østrem, Anders

AU - Reid, James

AU - van der Molen, Thys

PY - 2005/12

Y1 - 2005/12

N2 - Breathlessness, along with the associated inability to engage in normal activity, is one of the most distressing symptoms for patients with chronic obstructive pulmonary disease (COPD). If treatment for breathlessness is started early in the disease, physical activity could, in theory, be improved or maintained; this may slow the progression of symptoms towards disability and improve quality of life. A significant cause of breathlessness in COPD is hyperinflation of the lungs due to air trapping, which occurs largely as a result of airflow limitation. Regular exercise reduces the respiratory demand of muscles and, by inference, the impact of air trapping during less intensive activities. Moreover, although airflow limitation in COPD is poorly responsive to anti-inflammatory drugs and less responsive to bronchodilators than in asthma, bronchodilators are clinically proven to bring perceivable symptom improvements in COPD. These improvements correlate with improvements in air trapping indices, which can be significant even in the absence of significant change in forced expiratory volume in 1 second (FEV(1)). The rationale for treatment in COPD, therefore, differs to that for asthma. Understanding of the pathophysiology of COPD improves our chances of achieving an effective intervention with the hope of a better quality of life for patients.

AB - Breathlessness, along with the associated inability to engage in normal activity, is one of the most distressing symptoms for patients with chronic obstructive pulmonary disease (COPD). If treatment for breathlessness is started early in the disease, physical activity could, in theory, be improved or maintained; this may slow the progression of symptoms towards disability and improve quality of life. A significant cause of breathlessness in COPD is hyperinflation of the lungs due to air trapping, which occurs largely as a result of airflow limitation. Regular exercise reduces the respiratory demand of muscles and, by inference, the impact of air trapping during less intensive activities. Moreover, although airflow limitation in COPD is poorly responsive to anti-inflammatory drugs and less responsive to bronchodilators than in asthma, bronchodilators are clinically proven to bring perceivable symptom improvements in COPD. These improvements correlate with improvements in air trapping indices, which can be significant even in the absence of significant change in forced expiratory volume in 1 second (FEV(1)). The rationale for treatment in COPD, therefore, differs to that for asthma. Understanding of the pathophysiology of COPD improves our chances of achieving an effective intervention with the hope of a better quality of life for patients.

U2 - 10.1016/j.pcrj.2005.08.005

DO - 10.1016/j.pcrj.2005.08.005

M3 - Article

VL - 14

SP - 285

EP - 293

JO - Primary Care Respiratory Journal

JF - Primary Care Respiratory Journal

SN - 1471-4418

IS - 6

ER -